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Hyperhomocysteinemia Is Associated With an Increased
Risk of Cardiovascular Disease, Especially in
Non–Insulin-Dependent Diabetes Mellitus
A Population-Based Study
Ellen K. Hoogeveen, Pieter J. Kostense, Pieter J. Beks, Albert J.C. Mackaay, Cornelis Jakobs,
Lex M. Bouter, Robert J. Heine, Coen D.A. Stehouwer
Abstract—A high serum total homocysteine (tHcy) level is an independent risk factor for cardiovascular disease. Because it
is not known whether the strength of the association between hyperhomocysteinemia and cardiovascular disease is similar
for peripheral arterial, coronary artery, and cerebrovascular disease, we compared the three separate risk estimates in an
age-, sex-, and glucose tolerance–stratified random sample (n5631) from a 50- to 75-year-old general white population.
Furthermore, we investigated the combined effect of hyperhomocysteinemia and diabetes mellitus with regard to
cardiovascular disease. The prevalence of fasting hyperhomocysteinemia (.14.0 mmol/L) was 25.8%. After adjustment for
age, sex, hypertension, hypercholesterolemia, diabetes, and smoking, the odds ratios (ORs; 95% confidence intervals) per
5 -mmol/L increment in tHcy were 1.44 (1.10 to 1.87) for peripheral arterial, 1.25 (1.03 to 1.51) for coronary artery, 1.24
(0.97 to 1.58) for cerebrovascular, and 1.39 (1.15 to 1.68) for any cardiovascular disease. After stratification by glucose
tolerance category and adjustment for the classic risk factors and serum creatinine, the ORs per 5 -mmol/L increment in
tHcy for any cardiovascular disease were 1.38 (1.03 to 1.85) in normal glucose tolerance, 1.55 (1.01 to 2.38) in impaired
glucose tolerance, and 2.33 (1.11 to 4.90) in non–insulin-dependent diabetes mellitus (P5.07 for interaction). We
conclude that the magnitude of the association between hyperhomocysteinemia and cardiovascular disease is similar for
peripheral arterial, coronary artery, and cerebrovascular disease in a 50- to 75-year-old general population. High serum
tHcy may be a stronger (1.6-fold) risk factor for cardiovascular disease in subjects with non–insulin-dependent diabetes
mellitus than in nondiabetic subjects. (Arterioscler Thromb Vasc Biol. 1998;18:133-138.)
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Retrospective and prospective studies have demonstratedthat hyperhomocysteinemia is a risk factor for cardiovas-
cular disease that is independent of classic risk factors such as
smoking, hypercholesterolemia, diabetes mellitus, and hyper-
tension.1–4 In a recent meta-analysis,1 the association between
hyperhomocysteinemia and peripheral arterial disease (summa-
ry OR, 6.8) was considerably stronger than with coronary
artery and cerebrovascular disease (ORs, 1.8 and 1.5). The
summary estimate of the association between hyperhomocys-
teinemia and peripheral arterial disease, however, was inferred
from one population-based study,5 which consisted of only
men, and two hospital-based studies.6,7 Therefore, to further
investigate this issue, we compared the risk estimates of
peripheral arterial, coronary artery, and cerebrovascular disease
in a random sample of a 50- to 75-year-old general white
population.
A recent large study showed that the risk of cardiovascular
disease was especially high among subjects with hyperhomo-
cysteinemia who also smoked or had hypertension, ie, there
was evidence of interaction with these risk factors.2 However,
this study excluded diabetic subjects. Our study was specifically
designed to examine glucose tolerance as a cardiovascular risk
factor,8 and therefore we investigated the combined effect of
hyperhomocysteinemia and diabetes mellitus with regard to
relative risk of cardiovascular disease.
Finally, there is increasing evidence that hyperhomocys-
teinemia is common in the elderly population.9,10 A large part
of the prevalence of hyperhomocysteinemia in the elderly
population is attributable to a low intake of the B vitamins,
folate, vitamin B6, and vitamin B12.10 Therefore, it has been
suggested that lowering serum tHcy levels by increasing the
intake of folate, probably the most important dietary determi-
nant of serum tHcy levels, may be an effective means of
decreasing cardiovascular risk.11 To estimate the potential
maximum benefit of such a strategy, we estimated the propor-
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tion of preventable cardiovascular disease caused by
hyperhomocysteinemia.
Methods
Design and Study Population
The Hoorn Study is a cross-sectional survey of glucose tolerance and
other cardiovascular risk factors in a 50- to 75-year-old general white
population conducted from 1989 to 1992. A random sample of all
men and women aged 50 to 75 years was drawn from the municipal
population registry office of Hoorn (The Netherlands); 2484 subjects
participated (response rate, 71%). An extensive cardiovascular inves-
tigation (detailed below) was performed in an age-, sex-, and glucose
tolerance–stratified random subsample (n5631; response rate,
89.1%).8 The Hoorn Study was approved by the Ethical Review
Committee of the University Hospital Vrije Universiteit. Informed
consent was obtained from all participants.
Cardiovascular Disease
Cardiovascular disease was defined as coronary artery, cerebrovascular,
or peripheral arterial disease. Coronary artery disease was defined as a
history of myocardial infarction, coronary artery bypass grafting, or
Minnesota codes 1–1 or 1–2 on the ECG (n5625).12 Cerebrovascular
disease was defined as a history of TIA or stroke, or a carotid artery
stenosis of .80%. (A carotid artery stenosis in excess of 80% is
associated with a high risk of stroke within 2 years: more than 25% for
symptomatic and 10% for asymptomatic carotid stenosis.13,14) Periph-
eral arterial disease was defined as a peripheral arterial reconstruction
or limb amputation, or an ABPI ,0.50. (A low ABPI is related to
both more extensive peripheral arterial disease and a higher risk of
cardiovascular mortality.15–18) The cardiovascular history was obtained
by means of a self-administered questionnaire and, if positive, accepted
only when confirmed by written information from the participant’s
general practitioner. Ultrasonographic examination of both common,
internal, and external carotid arteries (n5628) was performed by
means of a color-coded Duplex scanner as previously described in
detail.19 We classified subjects into two categories on the basis of the
maximal percentage of stenosis of the more diseased of the two carotid
arteries: 0% to 80% or 81% to 100%.20 The ABPI was obtained by
means of Doppler-assisted systolic blood pressure measurements taken
from the brachial and the three crural arteries on both sides as
previously described in more detail.8 The lowest ABPI of either limb
was used for statistical analysis.
Measurement of Serum Total Homocysteine
Fasting blood samples were centrifuged within 1 hour after collection.
Serum was stored at 220°C for 4 to 6 years. There is good evidence that
serum tHcy levels are stable for 10 years or more.9,21 Serum total (free plus
protein bound) homocysteine level was measured by using tri-n-bu-
tylphosphine as the reducing agent and ammonium 7-fluorobenzo-2-
oxa-1,3-diazole-4-sulfonate as the thiol-specific fluorochromophore, fol-
lowed by high-performance liquid chromatography with fluorescence
detection.22 The intra-assay and interassay coefficients are 2.1% and 5.1%.
Other Cardiovascular Risk Factors
We measured levels of fasting serum total cholesterol, HDL choles-
terol, triglycerides (enzymatic techniques, Boehringer Mannheim),
and creatinine (modified Jaffe´ method). HbA1c was determined by
ion-exchange high-performance liquid chromatography. Hypercho-
lesterolemia was defined as total cholesterol $6.5 mmol/L or the
current use of cholesterol-lowering medication. Hypertension was
defined as a blood pressure $160 mm Hg systolic, $95 mm Hg
diastolic, or the current use of antihypertensive medication. IGT and
NIDDM were defined according to the World health Organization
criteria23 applied to the mean of two oral glucose tolerance tests.
Subjects were classified as either nonsmokers or ever smokers. BMI
and waist-hip ratio were calculated as described elsewhere.8 All
laboratory and vascular measurements and codings of the ECGs were
carried out in a blinded fashion with respect to history of cardiovas-
cular disease and glucose tolerance status.
Statistical Analysis
Variables are presented as mean6SD, number (percentage of the
total), or in case of skewed distribution, median and IQR. Associa-
tions of cardiovascular risk factors with serum tHcy level (logarithmi-
cally transformed) were studied by calculating Pearson correlation
coefficients. All reported probability values are two-tailed. We assessed
sex-specific prevalences of hyperhomocysteinemia for different cutoff
values (.12, 13, 14, 15, and 16 mmol/L), standardized for age and
glucose tolerance as described previously in detail.8 Briefly, the
frequency of hyperhomocysteinemia was determined in 24 strata (age
[3], sex [2], and glucose tolerance [4]) of the subsample. To assess the
prevalence of hyperhomocysteinemia in the original population-based
sample (standard, n52484), the prevalence of hyperhomocysteinemia
was back-calculated from the magnitude of each age, sex, and glucose
tolerance category stratum.
We performed logistic regression analyses to study the association of serum
tHcy with peripheral arterial, coronary artery, and cerebrovascular disease
separately and combined (ie, total cardiovascular disease). We calculated ORs
and 95% CIs per 5-mmol/L (about 1 SD) increment of serum tHcy (assuming
a linear logistic relationship between homocysteine and risk of cardiovascular
disease) and by tertiles with the lowest tertile as a reference category. We used
multiple logistic regression analysis to control for age, sex, hypertension,
hypercholesterolemia, smoking, and diabetes mellitus. We also tested models
that also included serum creatinine, total cholesterol, triglycerides, HDL and
LDL cholesterol, systolic blood pressure, BMI, or waist-hip ratio. To evaluate
a possible modifying role of other risk factors, we repeated the previous
analyses in strata of sex, glucose tolerance categories, smoking, hypertension,
and hypercholesterolemia.
We calculated the PAR, ie, the percentage of excess cardiovascular
disease in the population attributable to elevated serum total homo-
cysteine levels, as [Pe(RR21)3100]/[Pe(RR21)11], where RR is
the relative risk estimated as the OR, and Pe is the proportion of the
population liable to benefit from a reduction of serum tHcy levels.
The potential benefit of a distribution shift of 5 mmol/L was calculated
because we assumed that this is within attainable limits.1 To calculate
the PAR, we conservatively assumed that reduced serum tHcy level
would benefit only individuals with levels higher than 12 mmol/L,
although the epidemiological evidence more strongly supports a
graded than a threshold association between serum tHcy and cardio-
vascular disease. The cutoff of 12 mmol/L is based on homocysteine
levels of vitamin B12- and folate-replete subjects10,24,25 and thus on
nutritional status, not on an estimate of the association with cardio-
vascular disease. This calculation of the PAR assumes that there is no
important risk gradient up to a serum tHcy level of 12 mmol/L. To
investigate whether this assumption is reasonable, we also calculated
the ORs for cardiovascular disease for several ranges of homocysteine
concentrations with 9 to 12 mmol/L serum tHcy as the reference
category. We chose boundaries as small as possible to evaluate the
dose-response relationship between homocysteine and cardiovascular
disease as accurately as possible.
All analyses were performed with SPSS for Windows 6.1.
Selected Abbreviations and Acronyms
ABPI 5 ankle brachial pressure index
BMI 5 body mass index
CI 5 confidence interval
ECG 5 electrocardiogram
HbA1c 5 glycosylated hemoglobin
IGT 5 impaired glucose tolerance
IQR 5 interquartile range
NGT 5 normal glucose tolerance
NIDDM 5 non–insulin-dependent diabetes mellitus
OR 5 odds ratio
PAR 5 population-attributable risk
tHcy 5 total homocysteine
TIA 5 transient ischemic attack
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Results
Table 1 shows the main characteristics of the study population.
The median serum tHcy level was 12.2 (IQR, 10.0 to
15.3) mmol/L in men and 10.7 (IQR, 9.0 to 13.3) mmol/L in
women. Fig 1 shows the standardized sex-specific prevalences
of hyperhomocysteinemia according to different cutoff values.
The medians (IQR) for serum tHcy were 11.2 (9.2 to
14.4) mmol/L in NGT, 12.2 (9.7 to 14.5) mmol/L in IGT, and
11.2 (9.2 to 13.6) mmol/L in NIDDM. Serum tHcy levels
correlated with age (r5.17; P,.0001), serum creatinine
(r5.41; P,.0001), systolic blood pressure (r5.10; P5.01),
waist-hip ratio (r5.12, P5.004), and inversely with HDL
cholesterol (r52.09; P5.03) but not with BMI (r52.02;
P5.6), fasting glucose (r52.07; P5.08), HbA1c (r52.02;
P5.7), or duration of NIDDM (r52.06, P5.6).
The mean6SD HbA1c was 5.360.5% in NGT, 5.660.5%
in IGT, and 7.261.8% in NIDDM. Of all NIDDM subjects,
96 (55.5%) were newly diagnosed. Ten (5.8%) were treated
with diet alone and 67 (38.7%) with glucose-lowering agents;
15 (8.7%) with insulin, 51 (29.5%) with sulfonylureas, and 3
(1.7%) with metformin (2 of whom also used sulfonylureas).
The median (IQR) duration of NIDDM of those subjects
treated with diet or glucose-lowering agents was 6.1 (2.5 to
11.2) years. The prevalence of cardiovascular disease was 7.3%
in NGT, 11.2% in IGT, and 15.6% in NIDDM.
A 5-mmol/L increment of serum tHcy was associated with
an increased risk of cardiovascular disease, which was of similar
magnitude in each of the vascular territories examined (Table
2). Additional adjustment for serum creatinine did not mate-
rially change the ORs, nor did inclusion of total cholesterol,
triglycerides, HDL and LDL cholesterol, systolic blood pres-
sure, BMI, or waist-hip ratio in the model. There was no
evidence for a threshold if risks were calculated by tertiles of
serum tHcy (data not shown). Risk of total cardiovascular
disease increased with increasing serum tHcy levels (Fig 2).
We evaluated possible effect modification and did not
observe substantial differences among the strata of the follow-
ing risk factors: male sex, hypertension, hypercholesterolemia,
and smoking (data not shown). However, after stratification by
glucose tolerance category, exclusion of one outlier, and
adjustment for age, sex, hypertension, hypercholesterolemia,
smoking, and serum creatinine, the ORs (95% CI) per
5-mmol/L increment in serum tHcy of cardiovascular disease
were 1.38 (1.03 to 1.85) in NGT, 1.55 (1.01 to 2.38) in IGT,
and 2.33 (1.11 to 4.90) in NIDDM (P5.07 for interaction; Fig
3). These results indicate that high serum tHcy is a stronger
(1.6-fold) risk factor for cardiovascular disease in NIDDM than
in subjects with normal or impaired glucose tolerance.
The standardized prevalence of cardiovascular disease was
8.0%. From the incremental PAR percent values for serum
tHcy levels .12 mmol/L, we calculated that the proportion of
preventable cardiovascular disease caused by a 5-mmol/L
decrease was 10.6% for a 50- to 75-year-old general white
population.
Discussion
There are four main findings in this study. First, the magnitude
of the association between hyperhomocysteinemia and cardio-
vascular disease was similar with respect to peripheral, coro-
nary, and cerebral arterial disease. Second, hyperhomocys-
teinemia appeared to be a stronger (1.6-fold) risk factor for
cardiovascular disease in subjects with NIDDM than in sub-
jects with normal or impaired glucose tolerance. Third, the
prevalence of hyperhomocysteinemia was high in this 50- to
75-year-old general population. Finally, we estimated a poten-
tial reduction of approximately 10% of the total burden of
cardiovascular disease by a distribution shift of 5 mmol/L serum
tHcy level.
In a recent meta-analysis,1 the summary ORs per 5-mmol/L
increment of fasting serum tHcy were 1.7 for coronary artery
disease, 1.5 for cerebrovascular disease, and 6.8 for peripheral
arterial disease. Compared with the ORs we found, these ORs
were somewhat higher for coronary and cerebrovascular dis-
ease but much higher for peripheral disease. For coronary and
peripheral arterial disease, it is unlikely that we underestimated
the relative risk because of misclassification of disease because
the diagnostic criteria we used are quite specific.8,14 In contrast,
the diagnostic category “TIA/stroke,” which was part of our
definition of cerebrovascular disease, included self-reported
TIAs, a diagnosis that is liable to nondifferential misclassifica-
tion. Thus, we may have underestimated the OR for cerebro-
TABLE 1. General Characteristics of Subjects
N 631
Men, % 48
Age, y 64.3 (7.2)
BMI, kg/m2 27.3 (4.0)
Waist-hip ratio 0.92 (0.09)
Ever smoker, % 66
Blood pressure, mm Hg
Systolic 139 (19)
Diastolic 83 (10)
Hypertension, % 39.1
Impaired glucose tolerance, % 26.9
Diabetes mellitus, % 27.4
Fasting glucose, mmol/L 6.7 (2.6)
HbA1c, % of hemoglobin 5.9 (1.3)
Total cholesterol, mmol/L 6.6 (1.2)
HDL cholesterol, mmol/L 1.3 (0.4)
LDL cholesterol, mmol/L 4.5 (1.1)
Triglycerides, mmol/L 1.6 (1.1-2.2)*
Creatinine, mmol/L 92 (19)
Total homocysteine, mmol/L 11.4 (9.3-14.1)*
Cardiovascular disease 67 (10.6)†
Peripheral arterial disease 17 (2.7)†
Coronary artery disease 40 (6.3)†
Cerebrovascular disease 19 (3.0)†
Cardiovascular disease indicates peripheral arterial disease, coronary artery
disease, and/or cerebrovascular disease; peripheral arterial disease indicates history
of vascular surgery or major amputation (n510) and/or ankle brachial pressure
index ,0.50 (n59); coronary artery disease indicates history of coronary artery
bypass grafting (n58), myocardial infarction (n524), and/or Minnesota codes 1-1
or 1-2 on the ECG (n519); and cerebrovascular disease indicates history of
TIA/stroke (n512) and/or carotid artery stenosis .80% (n58). Data are presented
as mean (SD), *median (interquartile range) or †number (percentage).
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vascular disease to some extent. Nevertheless, the results of the
present study clearly do not support the hypothesis that
hyperhomocysteinemia is a stronger risk factor for peripheral
arterial than for coronary and cerebrovascular disease, at least
among 50- to 75-year-olds. A recent study in younger subjects
(mean age, 45 years) reached a similar conclusion.2
Because the previously mentioned meta-analysis1 was based
mostly on studies that comprised to a large extent persons
younger than 55 years, another explanation for the weaker
association we found might be that the relative risk of
hyperhomocysteinemia with regard to cardiovascular disease is
weaker among older persons. However, in a recent study26 that
comprised subjects aged 25 to 65 years, an OR of 1.3 per
5-mmol/L increment of tHcy for severe coronary artery disease
was found, which is of a magnitude similar to the OR in the
present study.
Little is known about the impact of NIDDM on serum tHcy
levels. As in previous studies,27,28 we found no important
difference in fasting serum tHcy level between diabetic and
nondiabetic subjects. Although Araki et al29 and Munshi et al27
have demonstrated that diabetic subjects who also had macro-
vascular disease had a higher fasting and post–methionine load
tHcy level, respectively, than nondiabetic control subjects who
were free of cardiovascular disease, it is not clear from their
studies that the higher tHcy levels were due to the diabetic
state per se. In addition, we found no relationship between
serum tHcy and fasting glucose, HbA1c, or duration of
NIDDM. Although more than 55% of the diabetic subjects
Figure 1. Sex-specific prevalence of hyperhomocysteinemia in Hoorn, The Netherlands, between 1989 and 1992. Prevalences are pre-
sented for men and women separately for different cutoff values of serum tHcy.
TABLE 2. Odds Ratios (95% CIs) of Cardiovascular Disease per 5-mmol/L
Increment of Serum Total Homocysteine
Subjects, n Crude OR
Age- and Sex-
Adjusted OR
Multivariate*
Adjusted OR
Cardiovascular disease 67† 1.39‡ 1.34§ 1.39‡
(1.16-1.67) (1.12-1.60) (1.15-1.68)
Peripheral arterial disease 17 1.38§ 1.38§ 1.44§
(1.13-1.68) (1.12-1.69) (1.10-1.87)
Coronary artery disease 40 1.26§ 1.23\ 1.25\
(1.06-1.51) (1.02-1.47) (1.03-1.51)
Cerebrovascular disease 19 1.24\ 1.24 1.24
(1.01-1.54) (0.98-1.56) (0.97-1.58)
*Adjusted for age, sex, hypertension (yes/no), ever smoking (yes/no), hypercholesterolemia
(yes/no), and NIDDM (yes/no).
†Subjects were counted once with regard to cardiovascular disease end point.
‡P,.001; §P,.01; \P,.05.
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were newly diagnosed, we cannot rule out that changes of
dietary habits of the 45% of patients with diabetes who were
aware of their disease may have improved their B-vitamin
status and thereby lowered their tHcy level. There is no
indication that insulin or sulfonylureas alter tHcy metabolism.29
In contrast, metformin may induce vitamin B12 malabsorption
and thereby increase the serum tHcy level. However, we did
not find an important effect on serum tHcy levels in subjects
with NIDDM.30 Taken together, there is no clear evidence
that the diabetic state influences tHcy levels, but more detailed
studies of this issue are needed.
The design of the study, with oversampling of diabetic subjects,
provided an opportunity to investigate the combined role of
diabetes and hyperhomocysteinemia with regard to cardiovascular
disease. Because the oversampling was performed before identi-
fication of cardiovascular disease, there was no introduction of
bias. Hyperhomocysteinemia appeared to be a stronger risk factor
for cardiovascular disease in patients with NIDDM than in
subjects with normal or impaired glucose tolerance. The biolog-
ical mechanism for the interaction between diabetes and hyper-
homocysteinemia with regard to cardiovascular disease is not
known. However, both smoking and hypertension interact with
hyperhomocysteinemia.2 Taken together, these data suggest that
hyperhomocysteinemia can enhance atherogenic and/or throm-
bogenic pathways common to classic risk factors such as smoking,
hypertension, and diabetes mellitus. Because NIDDM is associ-
ated with a high risk of cardiovascular disease, interaction with
hyperhomocysteinemia may have important implications with
regard to risk management. The substantial difference we found
therefore merits further examination in a larger number of subjects
than were available in this study. In contrast to the findings of a
recent study,2 we found no interactions between serum tHcy and
other classic risk factors, but our study had limited power to do so.
Because the ORs for the three arterial territories did not
differ significantly, we calculated a summary OR for cardio-
vascular disease by pooling all subjects with coronary, periph-
eral, and/or cerebrovascular disease. We estimated a propor-
tion of preventable cardiovascular disease of 10% for a
distribution shift of 5 mmol/L serum tHcy level. A similar
result was obtained in a recent meta-analysis1: 10% of the
proportion of death caused by coronary heart disease was
estimated to be attributable to hyperhomocysteinemia. The
present study illustrates that although the OR of hyperhomo-
cysteinemia for cardiovascular disease is relatively modest,
hyperhomocysteinemia is an important risk factor because the
frequency is high in the general population. An increased risk
of cardiovascular disease has been observed if homocysteine
levels exceed 14 mmol/L.2–4 The prevalences of hyperhomo-
cysteinemia (.14.0 mmol/L) we found was 34% for men and
18% for women, which are somewhat higher than the 25% and
20% observed in a 67- to 74-year-old population of the
Framingham Study (based on plasma tHcy).10 Part of this
difference could be related to the fact that levels of serum
compared with plasma tHcy levels are slightly higher.31
A limitation of the present study is the absence of assessment
of serum folate, which would have provided important infor-
mation about the relation between serum tHcy and folate in
Figure 2. OR for cardiovascular
disease according to serum tHcy
level adjusted for age and sex. The
reference category was serum tHcy
values of 9 to 12 mmol/L. Percent-
ages of the subsample for each
serum tHcy range are presented.
The error bars represent the lower
or upper half of the 95% CI.
*P,.05, significantly different from
the reference category (A logarith-
mic scale was used because the
OR is a multiplicative measure of
association; equal differences on
the logarithmic scale correspond to
equal ratios between OR).
Figure 3. OR for cardiovascular disease after stratification by
glucose tolerance category. The error bars represent the upper
half of the 95% CI. ORs are calculated per 5-mmol/L increment
of serum tHcy, adjusted for age, sex, hypertension, ever smok-
ing, hypercholesterolemia, and serum creatinine. *P,.05;
P5.07 for interaction.
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the general population. However, additional measurements of
serum folate would not have altered the conclusions of the
present study with regard to the association between serum
tHcy and cardiovascular disease, because the associations be-
tween hyperhomocysteinemia and cardiovascular disease exist
regardless of the underlying cause of hyperhomocysteinemia.
Obviously, this cross-sectional study cannot resolve the tem-
poral relationship between homocysteine concentration and car-
diovascular disease. However, there is evidence that the relation
between tHcy and cardiovascular disease is causal because pro-
spective studies have shown a positive association between hy-
perhomocysteinemia and cardiovascular disease.3,4,32,33
In conclusion, hyperhomocysteinemia is positively associ-
ated with cardiovascular disease in a 50- to 75-year-old general
population, independent of classic risk factors. The magnitude
of the relative risk of hyperhomocysteinemia is similar with
regard to peripheral arterial, coronary arterial, and cerebrovas-
cular disease. With regard to cardiovascular disease, hyperho-
mocysteinemia appeared to be a stronger risk factor in patients
with NIDDM than in subjects with normal or impaired
glucose tolerance.
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